SEC Comment Letter 0000000000-26-002965 to FibroBiologics, Inc. (FBLG)

FibroBiologics, Inc.
Date: March 24, 2026 · CIK: 0001958777 · Accession: 0000000000-26-002965

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

March 24, 2026

Author

Division of

Form

UPLOAD

Company

FibroBiologics, Inc.

Letter

Re: FibroBiologics, Inc. Draft Registration Statement on Form S-1 Submitted March 20, 2026 CIK No. 0001958777 Dear Pete O Heeron:

March 24, 2026

Pete O Heeron Chief Executive Officer FibroBiologics, Inc. 455 E. Medical Center Blvd. Suite 300 Houston, TX 77598

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Barrett DiPaolo, Esq.

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 24, 2026

Pete O Heeron
Chief Executive Officer
FibroBiologics, Inc.
455 E. Medical Center Blvd.
Suite 300
Houston, TX 77598

 Re: FibroBiologics, Inc.
 Draft Registration Statement on Form S-1
 Submitted March 20, 2026
 CIK No. 0001958777
Dear Pete O Heeron:

 This is to advise you that we do not intend to review your registration
statement.

 We request that you publicly file your registration statement and
non-public draft
submission on EDGAR at least two business days prior to the requested effective
date and time.
Please refer to Rules 460 and 461 regarding requests for acceleration. We
remind you that the
company and its management are responsible for the accuracy and adequacy of
their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.

 Please contact Daniel Crawford at 202-551-7767 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Barrett DiPaolo, Esq.
</TEXT>
</DOCUMENT>

SecProbe.io